EC
BPMC

EntryPoint Capital’s Blueprint Medicines BPMC Stock Holding History

EntryPoint Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,586
Closed -$226K – 696
2024
Q4 		$226K Sell
2,586
-1,701
-40% -$156K 0.09% 532
2024
Q3 		$397K Buy
4,287
+2,998
+233% +$298K 0.23% 132
2024
Q2 		$139K Buy
+1,289
New +$129K 0.2% 149

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

EntryPoint Capital's BPMC Position: Q1 2025 in Review

EntryPoint Capital sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 2,586 shares — an estimated $226K sold.

EntryPoint Capital first reported a position in BPMC in Q2 2024 and held it in 3 quarters. The position peaked at $397K in Q3 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • EntryPoint Capital reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 2,586 Blueprint Medicines shares in Q1 2025, an estimated $226K.
  • EntryPoint Capital first reported a position in Blueprint Medicines in Q2 2024 and held it in 3 quarters.
  • EntryPoint Capital's Blueprint Medicines position peaked at $397K in Q3 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.